Urine Omics Predicting IO Therapy Responses in mUC Patients

Status Recruiting

Clinical Trial Summary

The study aims to identify urinary metabolite and protein markers that can predict anti-tumor efficacy and adverse events in subjects receiving IO-based therapies for metastatic urothelial carcinoma.

Clinical Trial Description

This is a multi-center single-arm translational study where patients with mUC who are about to receive pre-determined IO-based anti-tumor therapy will be invited to participate the study. After signing the approved informed consent, eligible and consenting subjects will donate their fresh urine samples for subsequent untargeted metabolomics and proteomics study via GS-MS/MS and/or LC-MS/MS to identify potential metabolite and protein markers that are able to predict efficacy and side effects of IO-based therapies. All subjects in the first-line, maintenance after 1st line, second-line, or subsequent lines of IO-based therapy will be invited and recruited, but those who have received any IO-based therapy before the study can NOT be recruited. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04641936
Study type	Observational
Source	National Taiwan University Hospital
Contact	Yeong Shiau Pu, MD PhD
Phone	886-2-23123456
Email	pu5249@ntuh.gov.tw
Status	Recruiting
Phase
Start date	December 17, 2020
Completion date	October 31, 2027

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05700344` - SOGUG-AVELUMAB_RWD
Recruiting	`NCT04623502` - An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy	N/A
Recruiting	`NCT05107674` - A Study of NX-1607 in Adults With Advanced Malignancies	Phase 1
Recruiting	`NCT04953104` - Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 Expression	Phase 2
Withdrawn	`NCT06050954` - A Pilot Study of Circulating Tumor DNA Adaptive Risk Maintenance Approach for Bladder Cancer (CARMA)	Phase 2
Active, not recruiting	`NCT03534804` - Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma	Phase 2
Active, not recruiting	`NCT00365157` - Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction	Phase 1/Phase 2
Withdrawn	`NCT06018116` - A Canadian Trial of Bicalutamide in Patients Receiving Maintenance Avelumab for Metastatic Urothelial Cancer.	Phase 2
Recruiting	`NCT04936230` - Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer	Phase 2
Recruiting	`NCT05544552` - Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations	Phase 1/Phase 2
Active, not recruiting	`NCT04514484` - Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV	Phase 1
Terminated	`NCT05052372` - Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib
Terminated	`NCT03115801` - A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers	Phase 2
Active, not recruiting	`NCT03854474` - Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma	Phase 1/Phase 2
Terminated	`NCT02693717` - Pemetrexed Disodium in Treating Patients With Previously Treated Metastatic Urothelial Cancer	Phase 2
Recruiting	`NCT04848519` - Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma	Phase 2
Active, not recruiting	`NCT04724018` - Sacituzumab Govitecan Plus EV in Metastatic UC	Phase 1
Terminated	`NCT04003610` - Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)	Phase 2
Recruiting	`NCT04383067` - A Phase 2, Single-Center, Open Label Study of Autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma Patients	Phase 2
Not yet recruiting	`NCT03108261` - Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations	Phase 2